{"id":"W4392615010","doi":"10.1093/ibd/izae024","title":"Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study","year":2024,"lang":"en","type":"article","venue":"Inflammatory Bowel Diseases","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; McGill University Health Centre","funders":"Genentech; Pfizer; Vifor Pharma; Amgen; Tillotts Pharma; United European Gastroenterology; Celltrion; Celgene; Biogen; Janssen Pharmaceuticals; Gilead Sciences; Eli Lilly and Company; Bristol-Myers Squibb; Falk Foundation","keywords":"Ulcerative colitis; Open label; Medicine; Internal medicine; Gastroenterology; Extension (predicate logic); Adverse effect; Disease; Computer science","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003337602,0.000348395,0.0004049614,0.00005059681,0.0001977744,0.0001124423,0.0003752861,0.00009815625,0.00001027349],"category_scores_gemma":[0.0004304553,0.0002647804,0.0002038908,0.00007084279,0.0002065435,0.00003103296,0.0002959574,0.00006648595,0.000004233591],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005446173,"about_ca_system_score_gemma":0.0004065551,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000102994,"about_ca_topic_score_gemma":0.000244209,"domain_scores_codex":[0.9976765,0.0003174989,0.0007360472,0.0007230541,0.000250862,0.0002960399],"domain_scores_gemma":[0.9982857,0.0003517992,0.0002290691,0.0007664005,0.0001850702,0.0001820079],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5352548,0.01780683,0.2109708,0.001604101,0.01866519,0.004962159,0.01806182,0.0009130496,0.1228855,0.00744149,0.01966283,0.04177147],"study_design_scores_gemma":[0.02840687,0.001445947,0.9588706,0.0004898843,0.001024477,0.000002987743,0.002957468,0.0002197942,0.003896977,0.0002130543,0.002017941,0.0004539299],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905323,0.002016922,0.0000282225,0.00007111562,0.0003005723,0.00327078,0.003536132,0.00003574346,0.0002082517],"genre_scores_gemma":[0.998492,0.0001113789,0.0001466599,0.00004951543,0.0002086179,0.0002767531,0.000480929,0.00005650859,0.0001776504],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7478998,"threshold_uncertainty_score":0.9999804,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0181372466786241,"score_gpt":0.2953979266882808,"score_spread":0.2772606800096567,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}